Profusa, Inc.

NovAcquisition Corp (Nasdaq: NVAC) is a healthcare-focused special purpose acquisition company that completed its initial public offering in 2021 and pursued a business combination with Profusa, Inc., a medical technology company developing implantable biosensor platforms designed for continuous in-body monitoring of physiological biomarkers such as oxygen and glucose. The Form 10-Q filed on August 11, 2022, under accession number 0001213900-22-046847, reflects the company's status during the de-SPAC process, with Profusa representing the operating target in the health tech sector. NVAC's sponsor structure is documented in SEC filings accompanying the deal. Sign up at SpacDesk for full data, filings history, and deal analytics on NVAC and hundreds of other SPACs.